WO2014147404A1 - Prenatal screening - Google Patents
Prenatal screening Download PDFInfo
- Publication number
- WO2014147404A1 WO2014147404A1 PCT/GB2014/050876 GB2014050876W WO2014147404A1 WO 2014147404 A1 WO2014147404 A1 WO 2014147404A1 GB 2014050876 W GB2014050876 W GB 2014050876W WO 2014147404 A1 WO2014147404 A1 WO 2014147404A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mass
- pregnancy
- sample
- pregnant woman
- urine
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/493—Physical analysis of biological material of liquid biological material urine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0027—Methods for using particle spectrometers
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/26—Mass spectrometers or separator tubes
- H01J49/34—Dynamic spectrometers
- H01J49/40—Time-of-flight spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
Definitions
- the present invention relates to a method for screening maternal urine samples for changes in the pattern of mass spectral fingerprinting which have been found to be characteristic of fetal aneuploidies such as Down's Syndrome and have application for the screening of other fetal abnormalities and disorders of pregnancy including gestational trophoblastic diseases.
- fetal aneuploidy such as Downs Syndrome, Patau syndrome Turner Syndrome, Klinefelter syndrome, Edwards syndrome and triple-X.
- the definitive test for Down's Syndrome in early pregnancy i.e. at about 15 to 16 weeks, is karyotyping following amniocentesis.
- the sampling of amniotic fluid required for this carries the risk of inducing spontaneous miscarriage, which may occur in about 1 in 100 cases.
- AFP Serum alpha-fetoprotein
- hCG human chorionic gonadotrophin
- uE 3 unconjugated estriol
- inhibin A have been added to the markers screened for.
- Screening performance varies according to the choice of markers used and whether ultrasound is used to estimate gestational age and to measure nuchal fold thickness at 15-22 weeks.
- the detection rate for a 5% false-positive rate is estimated to be 59% for the double test (AFP + hCG), 69% for the triple test (AFP,hCG, uE 3 ) and 76% for the quadruple test which includes inhibin A.
- Human chorionic gonadotropin is a glycopeptide hormone produced by the syncytiotrophoblasts of the fetal placenta, and has a molecular weight of about 38 kilodaltons. It can be detected by immunoassay in the maternal urine within days after fertilisation.
- the intact hCG molecule is a heterodimer comprising a specific ⁇ 25 subunit non-covalently bound to an a subunit, which is common to other glycoproteins.
- Maternal serum levels of both intact hCG and the free ⁇ - subunit are elevated on average in Down's Syndrome, but the extent of elevation is greater for 30 free ⁇ - hCG.
- HCG is detected in both the serum and urine of pregnant women, as are the free a and ⁇ subunits of hCG, as well as the degradation products of hCG and of free ⁇ - subunit hCG.
- the terminal degradation product of the ⁇ - subunit of hCG is urinary gonadotropin peptide (UGP), otherwise known as ⁇ - core - hCG, ⁇ - core fragment, ⁇ - core or urinary gonadotrophin fragment (uGF).
- UGP is excreted into urine.
- WO97/03363 describes a pre-natal urinary screening method for Down's Syndrome which comprises testing a maternal urine sample during the first trimester of pregnancy to determine whether the level of UGP in the sample is elevated above the level of UGP found in urine samples from normal 10 pregnancies. The method described in WO 97/03363 utilises immunoassays specific for UGP.
- hCG has been well characterised by HPLC-mass spectrometry and by crystallographic analysis.
- peptide mass mapping of hCG and its subunits has been carried out using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-ToF MS).
- MALDI-ToF MS matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
- WO03/065043 describes the immobilisation of immunoglobins on a MALDI-TOF MS target which may then be used in the identification and relative quantification of proteins such as hCGPcf.
- Human chorionic gonadotropin is a hetro-dimeric glycoprotein hormone with 8 glycosylation sites containing four N-linked oligosaccharides and four O-linked
- the N-linked oligosaccharides are attached to the polypeptide chain by ⁇ - N-glycosidic bonds on asparagine residues; two are on the a and two are on the ⁇ -subunit. They share the same basic structural characteristics: N-acetyl glucososamine (GLcNAc) is attached to an asparagine residue followed by another GLcNAc, mannose and two more branches of mannose. This is the monantennary pentasaccharide core with the remaining components being variable.
- the O-linked oligosaccharides are attached by a-O-glycosidic bonds onto serine residues of the ⁇ -subunit carboxyl terminal peptide.
- the degradation product of the ⁇ -subunit of hCG known as ⁇ -core fragment is composed of peptides from the ⁇ -subunit of hCG, i.e peptides ⁇ 6-40 and ⁇ 55-92, connected by four disulfide bridges. It retains many of the antigenic determinates of the original hCG ⁇ molecule prior to metabolism, which occurs primarily in the kidney.
- the ⁇ 6-40 polypeptide chain contains the two hCG ⁇ N-linked carbohydrate moieties, although the oligosaccharides are truncated due to metabolism.
- hCG glycosylation is extremely variable and hyperglycosylation of hCG occurs in disorders of pregnancy and fetal aneuploidies such as Down's Syndrome. It has now been found that, by subjecting unextracted, untreated urine samples obtained from pregnant women up to the second trimester, preferably between the 7th and 13th week of gestation, to MADLI-ToF MS analysis, a unique mass spectra is obtained which may show the change in pattern in glycosylation variants. These changes in pattern are indicative of the metabolic products of hyperglycosylated hCG that are characteristic of the glycosylation processes in cells of the trophoblast in disorders of pregnancy and fetal aneuploidy, and thus indicative of these conditions.
- a method of detecting a disorder of pregnancy or fetal aneuploidy up to the second trimester comprising, subjecting a maternal urine sample from a pregnant woman to direct mass spectral analysis, and comparing the patterns resulting from said analysis to mass spectral patterns obtained from normal pregnancies to determine whether said patterns from said sample are indicative of a disorder of pregnancy or fetal aneuploidy
- a method of detecting fetal aneuploidy up to the second trimester comprising subjecting a maternal urine sample from a pregnant woman to direct mass spectral analysis, and comparing the patterns resulting from said analysis to mass spectral patterns obtained from non-aneuploid pregnancies to determine whether said patterns from said sample are indicative of fetal aneuploidy
- the method of the invention provides a means of screening subjects to identify those mothers who are at risk of having or developing a disorder of pregnancy, or carrying an aneuploidy fetus.
- a disorder of pregnancy includes Ectopic pregnancy, Threatened
- the method of the invention provides a method of screening for pregnancy disorders which are already present when the sample is obtained such as Ectopic pregnancy, Threatened Miscarriage, Hyperemesis Gravidarum and Gestational Trophoblastic Diseases.
- the method of the invention can also provide an indication of the risk of developing other disorders of pregnancy which generally occur later in the pregnancy (i.e.
- fetal aneuploidy refers to a condition wherein the fetus has more or less than 46 chromosomes.
- the fetal aneuploidy is a trisomy disorder (e.g. Downs Syndrome, Patau syndrome and Edwards syndrome), more preferably Downs Syndrome.
- a trisomy disorder e.g. Downs Syndrome, Patau syndrome and Edwards syndrome
- Direct mass spectral analysis means that the data generated from the mass spectral analysis is used in the method, and not the inferred mass of the components present in the sample.
- the method of the invention is carried out on a sample obtained upto, and including the second trimester of pregnancy.
- the maternal urine sample is from a pregnant woman at between 7 and 16 weeks gestation, for example 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 weeks gestation. More preferably the maternal urine sample is from a pregnant woman at between 8 and 13 weeks gestation.
- the urine sample is a neat urine sample.
- the urine sample may be diluted or processed (concentrated, filtered, etc).
- the urine sample is diluted.
- the urine sample may be diluted 1/100 (i.e. one part sample in 100 parts diluent), 1/500, 1/1000, 1/2500 or more.
- the sample is diluted 1/1000 i.e one part urine sample in 1000 parts diluent.
- the diluent is water, more preferably deionized water.
- the urine sample is not processed prior to dilution.
- processing includes concentrating the proteins of interest e.g. hCG; isolating hCG by for example HPLC or treatment with a chemical agent to disrupt or break intramolecular bonds.
- the sample is preferably not treated with a reducing agent. More preferably the sample is not treated with dithiothrietol (DTT).
- DTT dithiothrietol
- the patterns of mass spectra are determined by an automated quantitative method that can distinguish between a mass spectrum of a urine sample from a normal pregnant woman and the mass spectral pattern of a urine sample from a pregnant woman with a pregnancy disorder or an aneuploidy fetus.
- a "normal" pregnant woman is one who does not have a pregnancy disorder and has a non-aneuploid fetus.
- an " automated quantitative method” refers to the processing by a computer software program of the direct output data from a mass spectrometer to which the sample was subjected.
- the patterns of mass spectra are determined by an automated quantitative method that can distinguish between a mass spectrum of a urine sample from a pregnant woman with a non-aneuploid fetus and the mass spectral pattern of a urine sample from a pregnant woman with an aneuploidy fetus.
- Methods of generating masss spectra such as MALDI- Tof MS, are commonly not quantitative technique.
- the Y axis in these spectra is an indicator of "relative strength" of mass peak within the spectra, but not between mass peak in one sample versus another sample.
- normalisation needs to render Y axis value comparable between sample spectra. Normalization is the process of producing a data structure to reduce repetition and inconsistencies of data. Several normalisation techniques are possible. Typical normalisation methods include percentage of total area at a given point, Square difference and ratio of differences. The percentage difference is calculated as
- Percentage difference ( Y ref - Yll Y ref X 100%) wherein Y ref is the minimum Y value of the spectra, and Yl is Y value for each point.
- the ratio difference is calculated as
- Ratio Difference ( Ratio 1 -Ratio 2)
- each sample is compared against a reference spectral model.
- the "reference spectral model” is the expected mass within a set range, determined from statistical analysis of a collection of normal pregnancy urine samples at matched gestational age.
- the range is between about 500 - 100,000m/z, for example 1,000 - 75,000 m/z, 2,500 - 50,000m/z , 5,000- 25,000m/z or 6,000 -14,000 m/z. Most preferably the range is 6,000 - 14,000 m/z .
- the spectral model of expected mass between about 6,000 -14,000 m/z is determined from statistical analysis of a collection of non-aneuploid pregnancy urine samples at matched gestational age.
- the spectral model is created by a method of data processing which results in a normalised statistically determined index of relative proportion of mass spectra within a set range. This renders all spectra comparable such that the median and centile variability at any given mass value can be modelled.
- the range is between about 6,000 -14,000 m/z.
- a parallel "disease" model as generated above from normalised statistically determined index of relative proportion of mass spectra within a set range is created from maternal urine obtained from a pregnant woman at between 8 and 16 weeks gestation with a disorder of pregnancy, or a fetal aneuploidy, for example Downs syndrome.
- the range is between about 6,000 -14,000 m/z.
- a normalised statistically determined index of relative proportion of mass spectra within a given range can be calculated from using the total area under the curve of mass spectra. This can then be used to calculate the relative intensity.
- the area under the curve of mass spectra is calculated by dividing the mass spectra into a plurality of bins of a given number of m/z.
- Bin has its usual statistical meaning ,for example, of being one of a series of ranges of numerical value into which data are sorted in statistical analysis.
- the bins can be 100m/z, 50m/z, 25m/z, lOm/z or 5m/z in size. The smaller the size of the bin used, the more refined the method.
- the relative intensity (Y Axis value) can be calculated by the "square of difference" method and therefore a comparable Y value given for every bin.
- the ratio of normalized spectral value of samples obtained from women with normal pregnancy and those from women suffering from a pregnancy disorder or with an aneuploidy fetus (mean, standard deviation, skewness, upper and lower quartile, median, kurtosis as well as 95th and 5th centile) at 7 to 16 weeks gestation can be calculated.
- the difference in relative intensity at each mass bin between samples obtained from women with normal pregnancy and those from women suffering from a pregnancy disorder or with an aneuploidy fetus at the respective gestational ages can be captured using commercially available statistical tests such as MATLAB ®, Stats DirectTM and Origin 8TM.
- the reference spectral model and the disease model are then compared by plotting (for example as shown in Figure 1) in order to identify 'hot spots' i.e. points of difference between the two models. This may be a decrease or increase in the size of a peak, or the appearance of a peak.
- the points of difference can then be used to determine the presence of an aneuploidy fetus, or likelihood of a pregnancy disorder. This may be done by using a suitable algorithm.
- the analysis of the mass spectra can be easily calculated using a suitable computer software program.
- a computer can also be programmed with the suitable algorithm in order to provide an indication of the presence of an aneuploidy fetus, or likelihood of a pregnancy disorder.
- the mass spectral analysis carried out is matrix-assisted laser
- MALDI-ToF MS desorption/ionization time-of-flight mass spectrometry
- Also described is a method of detecting a disorder of pregnancy or fetal aneuploidy up to the second trimester comprising a) obtaining a maternal urine sample form a pregnant woman;
- the method detects fetal aneuploidy, and the patterns resulting from the analysis are compared to those from a woman with a non-aneuploidy pregnancy.
- Figure 1 shows a comparison based on a least squared normalization technique for Downs and non-aneuploid pregnancies at 12-14 weeks gestation.
- Figure 2 is an illustration of a simple predictive algorithm for Downs Syndrome screening based on the spectral differences and comparison based on least squared normalization technique for Downs and non-aneuploid pregnancies at 12-14 weeks gestation.
- Figure 3 shows a comparison based on a least squared normalization technique for Downs and non-aneuploid pregnancies at 15-17 weeks gestation.
- Figure 4 is an illustration of a simple predictive algorithm for Downs Syndrome screening based on the spectral differences and comparison based on least squared normalization technique for Downs and non-aneuploid pregnancies at 15-17 weeks gestation as shown in Figure 3. Seven 'hot spots' were applied in a simple algorithm.
- Example 1
- the urine samples Prior to spotting onto the MALDI target plate for mass spectral analysis, the urine samples were spun down for 3 minutes at 1500 rpm to remove cellular debris. The sampels were diluted in deionized water to between 1/100 to 1/1000 (parts sample/water)
- MALDI plates (394 wells) were prepared by pipetting 0.5 ⁇ of sinnapinic acid matrix solution (20 mg/ml dissolved in 50/50v/v acetonitrile (ACN) and 0.1% trifluoacetic acid (TFA) in ddH20) and allowed to dry. A sample of diluted urine (0.5 ⁇ 1) was added and then allowed to dry, followed by the addition of a further 0.5 ⁇ 1 of sinnapinic acid matrix solution This was allowed to dry at room temperature for 1 hour before mass spectrometric analysis was performed.
- ACN acetonitrile
- TFA trifluoacetic acid
- the ions were accelerated by a 20 kV electrical field down a 1.2 m linear tube and detected by a micro-channel plate detector at a sampling rate of 500 MHz.
- Spectra were generated by summing 20-30 laser shots. A positive linear mode was used in order to acquire the spectra.
- Comma delimited data was then changed to M.file format in order to render it readable by MATLAB software.
- the total area under the curve of each sample within the mass range of 6,000- 14,000 m/z was calculated and the region was divided into 80 individual bins of 100 m/z unit.
- the relative intensity (Y Axis value) was calculated by the "square of difference” method and therefore a comparable Y value was given for every bin.
- the minimum Y value of the spectra (Y ref) was subtracted from the Y value at every bin and the difference was squared.
- the formula used to calculate square of difference (yl-yref) 2 and the calculated square of difference was then named as "relative intensity”.
- Computational models for assessing the relative level of spectral intensity of a fingerprint pattern between 6,000 to 14,000 m/z in Down's syndrome compared to uncomplicated singleton pregnancies was produced by plotting the median 95th and the 5th centile of the log of normalized area under the curve of every bin versus mass to charge ratio (m/z) from 6,000 to 14,000 Dalton from pregnancy urine at gestational age 12-13.
- Figure 1 of the accompanying diagrammatic drawings shows a comparison based on a least squared normalization technique for Downs and non-aneuploid pregnancies at 12-14 weeks gestation.
- Panel A shows overlaid average mass spectra with bin median as solid shapes and 5 and 95th centiles as whiskers for Downs (squares) and non-aneuploid (circles) pregnancies at 6000 to 14,000 m/z..
- Figure 2 of the accompanying diagrammatic drawings is an illustration of a simple predictive algorithm for Downs Syndrome screening based on the spectral differences and comparison based on least squared normalization technique for Downs and non-aneuploid pregnancies at 12-14 weeks gestation as shown in Figure 1.
- Three 'hot spots' were applied in a simple algorithm
- Predictive Algorithm score (m/z 11400) + (m/z 9200) / (m/z 6700).
- example 1 The methods of example 1 were repeated using samples of urine obtained during the second trimester, i.e. at 15, 16, and 17 weeks gestation.
- Figure 3 of the accompanying diagrammatic drawings shows a comparison based on a least squared normalization technique for Downs and non-aneuploid pregnancies at 15-17 weeks gestation.
- Panel A shows overlaid average mass spectra with bin median as solid shapes and 5 and 95th centiles as whiskers for Downs (squares) and non-aneuploid (circles) pregnancies at 6000 to 14,000 m/z..
- Figure 4 of the accompanying diagrammatic drawings is an illustration of a simple predictive algorithm for Downs Syndrome screening based on the spectral differences and comparison based on least squared normalization technique for Downs and non-aneuploid pregnancies at 15-17 weeks gestation as shown in Figure 3. Seven 'hot spots' were applied in a simple algorithm.
- Predictive Algorithm score (m/z 11300)+(m/z 11400)+(m/z 11500)+ (m/z 11600)+ (m/z 11700)+ (m/z 11800)+ (m/z 11900)
- Urine samples from women with gestational trophoblastic diseases were compared to samples obtained from women with a normal pregnancy.
- hCG fcf hyperglycosylation due to tri-antennary glycoforms was found to be the highest in the urine from women with molar and hyperemesis gravidarum pregnancies compared to the samples from normal pregnancy.
- hCG is N-linked hyperglycosylated to a greater extent in disease and abnormal pregnancy.
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/779,058 US10393729B2 (en) | 2013-03-22 | 2014-03-20 | Prenatal screening |
EP14712736.9A EP2976647B1 (en) | 2013-03-22 | 2014-03-20 | Prenatal screening |
CA2900333A CA2900333A1 (en) | 2013-03-22 | 2014-03-20 | Prenatal screening |
JP2016503723A JP6441892B2 (en) | 2013-03-22 | 2014-03-20 | Prenatal screening |
CN201480017541.3A CN105452868B (en) | 2013-03-22 | 2014-03-20 | Prenatal Screening |
BR112015024110A BR112015024110A2 (en) | 2013-03-22 | 2014-03-20 | method of detecting a pregnancy disorder or fetal aneuploidy by the second trimester |
EA201591682A EA201591682A1 (en) | 2013-03-22 | 2014-03-20 | PRENATAL SCREENING |
GB1518627.3A GB2531938A (en) | 2013-03-22 | 2014-03-20 | Prenatal screening |
AU2014234010A AU2014234010A1 (en) | 2013-03-22 | 2014-03-20 | Prenatal screening |
HK16102270.9A HK1214358A1 (en) | 2013-03-22 | 2016-02-26 | Prenatal screening |
HK16109803.0A HK1221767A1 (en) | 2013-03-22 | 2016-08-16 | Prenatal screening |
HK16109804.9A HK1221768A1 (en) | 2013-03-22 | 2016-08-16 | Prenatal screening |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1305317.8 | 2013-03-22 | ||
GBGB1305317.8A GB201305317D0 (en) | 2013-03-22 | 2013-03-22 | Prenatal screening for fetal abnormalities and disorders of pregnancy |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014147404A1 true WO2014147404A1 (en) | 2014-09-25 |
Family
ID=48326524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2014/050876 WO2014147404A1 (en) | 2013-03-22 | 2014-03-20 | Prenatal screening |
Country Status (11)
Country | Link |
---|---|
US (1) | US10393729B2 (en) |
EP (1) | EP2976647B1 (en) |
JP (1) | JP6441892B2 (en) |
CN (1) | CN105452868B (en) |
AU (1) | AU2014234010A1 (en) |
BR (1) | BR112015024110A2 (en) |
CA (1) | CA2900333A1 (en) |
EA (1) | EA201591682A1 (en) |
GB (2) | GB201305317D0 (en) |
HK (3) | HK1214358A1 (en) |
WO (1) | WO2014147404A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10504711B2 (en) | 2017-09-22 | 2019-12-10 | Bruker Daltonik Gmbh | Mass spectrometric method and MALDI-TOF mass spectrometer |
US10593532B2 (en) | 2018-02-19 | 2020-03-17 | Bruker Daltonik Gmbh | Liquid junction apparatus for electrospray ionization |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6338597B2 (en) | 2013-01-09 | 2018-06-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | Apparatus and method for fluorescence imaging using radio frequency multiplex excitation |
ES2959506T3 (en) | 2014-03-18 | 2024-02-26 | Univ California | Parallel flow cytometer using radiofrequency multiplexing, and method |
JP6856635B2 (en) | 2015-10-13 | 2021-04-07 | オメガ バイオシステムズ インコーポレイテッド | Multi-mode fluorescence imaging flow cytometry system |
AU2017234815B2 (en) | 2016-03-17 | 2022-11-03 | Becton, Dickinson And Company | Cell sorting using a high throughput fluorescence flow cytometer |
JP7023244B2 (en) * | 2016-05-12 | 2022-02-21 | ビーディー バイオサイエンス | Fluorescence imaging flow cytometry with improved image resolution |
US10006852B2 (en) | 2016-09-13 | 2018-06-26 | Becton, Dickinson And Company | Flow cytometer with optical equalization |
CN111202492B (en) * | 2018-11-20 | 2021-08-10 | 中国科学院上海营养与健康研究所 | Down syndrome dermatoglyph auxiliary screening built based on machine learning algorithm |
CN110808099B (en) * | 2019-03-27 | 2021-01-26 | 北京大学第三医院(北京大学第三临床医学院) | System for detecting ectopic pregnancy |
JP2022540601A (en) | 2019-07-10 | 2022-09-16 | ベクトン・ディキンソン・アンド・カンパニー | A reconfigurable integrated circuit for coordinating cell sorting |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5324667A (en) * | 1989-01-17 | 1994-06-28 | Macri James N | Method for detecting down sydrown by non-invasive maternal blood screening |
US5716853A (en) | 1995-07-07 | 1998-02-10 | Chiron Diagnostics Corporation | Prenatal down syndrome screening with assays specific for UGP |
WO2003065043A2 (en) | 2002-01-29 | 2003-08-07 | King's College London An Institute Incorporated By Royal Charter Of Strand | Identification and relative quantification of proteins |
US8068990B2 (en) * | 2003-03-25 | 2011-11-29 | Hologic, Inc. | Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids |
US7191068B2 (en) * | 2003-03-25 | 2007-03-13 | Proteogenix, Inc. | Proteomic analysis of biological fluids |
US7425700B2 (en) * | 2003-05-22 | 2008-09-16 | Stults John T | Systems and methods for discovery and analysis of markers |
US7991557B2 (en) * | 2004-06-19 | 2011-08-02 | Genenews Corporation | Computer system and methods for constructing biological classifiers and uses thereof |
WO2006034427A2 (en) * | 2004-09-20 | 2006-03-30 | Proteogenix, Inc. | Diagnosis of fetal aneuploidy |
EP1889088A2 (en) * | 2005-06-03 | 2008-02-20 | Cambridge Enterprise Limited | Biomarkers for psychotic disorders |
CN100410663C (en) * | 2005-09-11 | 2008-08-13 | 翁炳焕 | Proteomics ante partum diagnosis process |
WO2009059259A2 (en) * | 2007-10-31 | 2009-05-07 | Children's Hospital Medical Center | Detection of worsening renal disease in subjects with systemic lupus erythematosus |
JP2012093230A (en) * | 2010-10-27 | 2012-05-17 | St Marianna Univ School Of Medicine | Prediction method for curative effect of peginterferon and ribavirin combination therapy for hepatitis c and prediction kit used therefor |
EP2836833A4 (en) * | 2012-04-13 | 2015-10-14 | Univ Wayne State | Prenatal screening for down syndrome and trisomy 18 |
-
2013
- 2013-03-22 GB GBGB1305317.8A patent/GB201305317D0/en not_active Ceased
-
2014
- 2014-03-20 EP EP14712736.9A patent/EP2976647B1/en active Active
- 2014-03-20 WO PCT/GB2014/050876 patent/WO2014147404A1/en active Application Filing
- 2014-03-20 US US14/779,058 patent/US10393729B2/en active Active
- 2014-03-20 JP JP2016503723A patent/JP6441892B2/en active Active
- 2014-03-20 EA EA201591682A patent/EA201591682A1/en unknown
- 2014-03-20 AU AU2014234010A patent/AU2014234010A1/en not_active Abandoned
- 2014-03-20 CN CN201480017541.3A patent/CN105452868B/en active Active
- 2014-03-20 CA CA2900333A patent/CA2900333A1/en not_active Abandoned
- 2014-03-20 BR BR112015024110A patent/BR112015024110A2/en not_active IP Right Cessation
- 2014-03-20 GB GB1518627.3A patent/GB2531938A/en not_active Withdrawn
-
2016
- 2016-02-26 HK HK16102270.9A patent/HK1214358A1/en unknown
- 2016-08-16 HK HK16109804.9A patent/HK1221768A1/en unknown
- 2016-08-16 HK HK16109803.0A patent/HK1221767A1/en unknown
Non-Patent Citations (2)
Title |
---|
E.S. JACOBY ET AL.: "Determination of the glycoforms of human chorionic gonadotropin beta-core fragment by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.", CLINICAL CHEMISTRY, vol. 46, no. 11, 2000, Winston-Salem NC USA, pages 1796 - 1803, XP055122843 * |
S MALATOS ET AL: "Analysis of hCG beta core fragment glycosylation in normal and aberrant pregnancy by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry", 23RD JOINT MEETING OF THE BRITISH ENDOCRINE SOCIETIES WITH THE EUROPEAN FEDERATION OF ENDOCRINE SOCIETIES BRIGHTON, UK 22 MARCH 2004 - 24 MARCH 2004, 22 March 2004 (2004-03-22), Bristol, pages 195, XP055122838 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10504711B2 (en) | 2017-09-22 | 2019-12-10 | Bruker Daltonik Gmbh | Mass spectrometric method and MALDI-TOF mass spectrometer |
DE102017008885B4 (en) | 2017-09-22 | 2024-04-25 | Bruker Daltonics GmbH & Co. KG | Mass spectrometric method and MALDI-TOF mass spectrometer |
US10593532B2 (en) | 2018-02-19 | 2020-03-17 | Bruker Daltonik Gmbh | Liquid junction apparatus for electrospray ionization |
Also Published As
Publication number | Publication date |
---|---|
EA201591682A1 (en) | 2016-02-29 |
HK1221767A1 (en) | 2017-06-09 |
AU2014234010A1 (en) | 2015-08-20 |
BR112015024110A2 (en) | 2017-07-18 |
HK1221768A1 (en) | 2017-06-09 |
GB201305317D0 (en) | 2013-05-08 |
EP2976647A1 (en) | 2016-01-27 |
US20160054293A1 (en) | 2016-02-25 |
JP6441892B2 (en) | 2018-12-19 |
JP2016518591A (en) | 2016-06-23 |
HK1214358A1 (en) | 2016-07-22 |
US10393729B2 (en) | 2019-08-27 |
CA2900333A1 (en) | 2014-09-25 |
GB2531938A (en) | 2016-05-04 |
CN105452868B (en) | 2019-04-19 |
EP2976647B1 (en) | 2019-05-15 |
CN105452868A (en) | 2016-03-30 |
GB201518627D0 (en) | 2015-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2976647B1 (en) | Prenatal screening | |
JP7385951B2 (en) | Pairs of biomarkers to predict preterm birth | |
EP1996923B1 (en) | Methods for distinguishing isomers using mass spectrometry | |
WO2008085036A1 (en) | Peptide markers for diagnosis of preeclampsia | |
Ravnsborg et al. | First-trimester multimarker prediction of gestational diabetes mellitus using targeted mass spectrometry | |
Iles et al. | Direct and rapid mass spectral fingerprinting of maternal urine for the detection of Down syndrome pregnancy | |
EP3186641B1 (en) | Rapid screening and evaluation of diabetes and prediabetes by glycated hemoglobin mass spectrometry | |
US7572639B2 (en) | Method and apparatus for predicting pregnancy outcome | |
EP3143409A2 (en) | Early placenta insulin-like peptide (pro-epil) | |
EP3198279B1 (en) | Method of providing a prognosis of successful implantation of a cultured embryo | |
Gupta et al. | Altered proteome profiles in maternal plasma in pregnancies with fetal growth restriction: Haptoglobin α2 isoform as a potential biomarker | |
CN117079823B (en) | System and method for early predictive selective fetal growth-limited morbidity risk screening | |
CN117233367B (en) | Metabolic marker for pregnancy hypertension risk assessment | |
Barbacane et al. | P06. 11: Evaluation of PAPP-A and free beta hCG in enlarged nuchal translucency: benefit in first trimester screening. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480017541.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14712736 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2900333 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2014234010 Country of ref document: AU Date of ref document: 20140320 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016503723 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14779058 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201591682 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014712736 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 201518627 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20140320 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1518627.3 Country of ref document: GB |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015024110 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015024110 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150918 |